Dr Michael Baker interview with Stockhead
Stockhead’s Tylah Tully chats with Dr Michael Baker, Arovella managing director and CEO, on how the company’s soon-to-be-granted US patent for its CAR-iNKT cell therapy platform marks a major milestone in strengthening IP protection in a key global market.
